| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TVTX | Common Stock | Options Exercise | +8,000 | +9.5% | 92,170 | 10 Feb 2025 | Direct | F1, F2 | ||
| transaction | TVTX | Common Stock | Sale | $60,426 | -2,568 | -2.8% | $23.53 | 89,602 | 12 Feb 2025 | Direct | F3 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TVTX | Performance-based restricted stock units | Options Exercise | $0 | -8,000 | -100% | $0.000000 | 0 | 10 Feb 2025 | Common Stock | 8,000 | Direct | F1, F2 |
| Id | Content |
|---|---|
| F1 | On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 8,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain clinical/regulatory performance criteria. On February 10, 2025, the PSUs vested upon the Issuer's confirmation that the clinical/regulatory performance criteria had been satisfied, including confirming a path forward for submitting an sNDA for traditional approval of FILSPARI (sparsentan) in FSGS. |
| F2 | Each PSU represents a contingent right to receive one share of the common stock of the Issuer. |
| F3 | Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested PSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. |